Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

STATUS

Recruiting
End date

Apr 25, 2024
participants needed

37
sponsor

Memorial Sloan Kettering Cancer Center

Send

Updated on 4 October 2022

See if I qualify

radical cystectomy

cancer

carcinoma

metastasis

neutrophil count

lymphadenectomy

pembrolizumab

carcinoma in situ

bladder cancer

invasive bladder cancer

transurethral resection

bladder tumor

intravesical bcg

Summary

The purpose of this study is to find out the effectiveness of pembrolizumab in combination with BCG as a first line therapy for participants with high grade T1 bladder cancer who are at "high risk" for BCG alone to be ineffective and are seeking an alternative treatment option to radical cystectomy. There is biologic rationale for combining pembrolizumab and BCG as two distinct immunotherapies with possible additive or synergistic activity in urothelial cancer. The combination of pembrolizumab with BCG will also be evaluated in an exploratory cohort of patients with upper tract urothelial cancer.

Description

Patients will receive pembrolizumab (MK-3475) administered after TUR in combination with BCG as initial therapy. Pembrolizumab (MK-3475) will be administered as a 400 mg IV infusion at 6-week intervals (Q6W) for 9 doses over a 48 week period, unless there is unacceptable toxicity or other reasons that would warrant the discontinuation of treatment. Patients will receive once-weekly BCG therapy (TICE strain, 50 mg) for 6 consecutive weeks as a standard induction course, given as intravesical BCG for patients with T1 bladder cancer, and administered through a percutaneous nephrostomy tube in antegrade fashion for patients with high-grade NMI-UTUC, consistent with standard clinical practice. BCG will start on week 3 after the first infusion of pembrolizumab (400 mg) to allow for initial priming of T cells to further enhance the effects of BCG treatment. Initiation of induction BCG may be delayed (up to 14 days) if deemed clinically indicated by the treating physician due to side effects from TURBT or ureteroscopy and with permission from the Principal Investigator (PI).

Details

Condition	Bladder Cancer
Treatment	pembrolizumab (MK-3475), Bacillus Calmette-Guérin (BCG)
Clinical Study Identifier	NCT03504163
Sponsor	Memorial Sloan Kettering Cancer Center
Last Modified on	4 October 2022

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Be willing and able to provide written informed consent/assent for the trial
	Histologically confirmed urothelial cancer by TURBT performed at MSK for patients in the T1 bladder cancer cohort or by high-grade cytology/biopsy by ureteroscopy performed at MSK for patients in the NMI-UTUC cohort
	TURBT within 6 weeks of protocol entry with complete resection of all papillary lesions for patients in the T1 bladder cancer cohort and ureteroscopy within 6 weeks of protocol entry with complete ablation of all papillary lesions with ureteroscopy or through antegrade percutaneous access for patients in the NMI-UTUC cohort
	Patients in the T1 bladder cancer cohort must have high risk, BCG-naïve non-muscle-invasive urothelial cancer defined as having one of the following disease
	states
	T1 on restaging biopsy, plus CIS
	Multiple (≥ 1) T1 recurrences, plus CIS
	Multifocal T1 plus CIS
	T1b (extensive/deep invasion into lamina propria) plus CIS
	Lymphovascular invasion plus CIS
	T1 with variant histology: including micropapillary, nested variant, poorly differentiated, squamous, and glandular differentiation (the presence of variant histology will be based on MSKCC review), plus CIS
	T1 with urothelial carcinoma of prostatic urethra (Ta, Tis, or T1 within prostatic urethra), plus CIS
	Large (≥3 cm) T1 tumor, plus CIS
	Patients in the NMI-UTUC cohort must have high risk, BCG naïve NMI-UTUC, defined by
	having one of the following disease states
	Histologic confirmed ureteroscopic biopsy with clinical stage Tis (also known as CIS), Ta, or T1 disease in the renal pelvis. Concomitant ureteral disease will be allowed if completely treated endoscopically
	Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy
	Clinical stage Tis confirmed by a positive high-grade selective cytology, coupled with ureteroscopic evaluation, confirming only flat eryethematous lesions and the absence of papillary tumors
	Patients must have cross sectional imaging (CT or MRI urogram) within 3 months of
	protocol entry demonstrating no evidence of metastasis or radiographic
	evidence of muscle invasive disease
	Patient refusal of cystectomy and bilateral pelvic lymphadenectomy for the T1 bladder cancer cohort, or refusal of radical nephroureterectomy for NMI-UTUC cohort
	Hemoglobin ≥ 9 g/dL
	Bilirubin ≤ 1.5 times the upper limit of normal (x ULN)
	No prior intravesical BCG therapy for patients in the T1 bladder cancer cohort
	No prior radiation therapy for bladder cancer for patients in the T1 bladder cancer cohort. Prior radiation therapy for prostate cancer is allowed
	Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x ULN
	Calculated creatinine clearance ≥ 30 using the CKD-Epi formula
	ECOG performance status of 0 or 1
	Age ≥ 18 years
	Female subjects of childbearing potential must be willing to use 2 methods of birth control, be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of the study medication (reference section 9.5.2). Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for >1 year
	Patients must not have other invasive malignancies within the past 5 years (with the exception of non-melanoma skin cancers, localized prostate cancer, and CIS of the cervix)
	Required initial laboratory values
	Absolute neutrophil count ≥ 1.5 x 10^9/L
	Platelets ≥ 100 x 10^9/L
Exclusion Criteria
	Unstable angina
	New York Heart Association (NYHA) Grade II or greater congestive heart failure
	History of myocardial infarction within 6 months
	History of stroke within 6 months
	Evidence of bleeding diathesis or coagulopathy
	Pregnant (positive pregnancy test) or lactating
	Serious, non-healing wound, ulcer, or bone fracture
	Inability to comply with study and/or follow-up procedures
	Prior therapy with an anti-PD-1 agent, anti-PD-L1 agent, or other inhibitory or stimulatory agent oriented towards a T-cell receptor
	Current or History of muscle invasive bladder cancer or prostatic stromal invasion
	Active infection requiring systemic therapy
	Known history of human immunodeficiency virus (HIV)
	Known active Hepatitis B or Hepatitis C
	Received live attenuated vaccines within 30 days prior to start of study treatment. Patients must also agree to avoid live attenuated vaccines during study treatment
	Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic or immunosuppressive agents. Subjects with vitiligo, diabetes Type I, or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators, inhaled steroids, or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjøgren's syndrome will not be excluded from the study
	Presence of any systemic metastases (i.e, nodal, visceral, or central nervous system)
	Major surgical procedure (other than TURBT or ureteroscopy) within 28 days prior to the study
	Known contraindications to BCG, defined as one of the following
	History of systemic hypersensitivity reaction or history of febrile systemic BCG reaction
	Febrile illness or persistent gross hematuria
	Active tuberculosis
	Immunosuppression due to congenital or acquired immune deficiency, concurrent immune suppressive disease, systemic cancer therapy, or chronic immunosuppressive therapy other than topical or inhaled corticosteroids

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

invasive bladder cancer

transurethral resection

bladder tumor

intravesical bcg

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Edit Delete

Added by •

•

Private

Edit Delete

Reply by • • Private

Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

Enter the passcode

The passcode will expire in None.

Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]